Betadex Sulfobutyl Ether Sodium SBECD Pharma Grade API is a polyanionic β-cyclodextrin derivative produced by reacting native β-cyclodextrin with 1,4-butanesultone under alkaline conditions, followed by neutralization and purification. The product model is SBECD Pharma Grade API, degree-of-substitution 6.2–6.9 sodium salt, allocated for oral solid and injectable applications. It is supplied as a white to off-white amorphous powder with a number-average molecular weight near 2163 g/mol and published aqueous solubility above 500 mg/mL at 25 °C. Compendial identities include USP-NF Betadex Sulfobutyl Ether Sodium and Ph. Eur. Sulfobutylether-β-cyclodextrin sodium. The primary function is reversible inclusion complexation of poorly water-soluble active pharmaceutical ingredients in tablets, capsules, granules, and injections. The terminal sulfonate group of each sulfobutyl ether substituent remains ionized across the physiological pH range, which distinguishes SBECD from neutral native β-cyclodextrin and non-ionic hydroxypropyl betadex. In solid oral and parenteral formulations, SBECD increases apparent aqueous solubility, stabilizes labile APIs, and modifies dissolution or release rate; the exact effect is controlled by drug geometry, ionization state, and ionic strength of the medium.

What Are the Critical Compendial Boundaries for Injectable-Grade SBECD?

Injectable-grade material requires tighter control of residual β-cyclodextrin and process impurities than oral grade. The average degree of substitution is measured by capillary electrophoresis or NMR using the monograph method; the accepted range is 6.2–6.9 because lower substitution increases residual β-cyclodextrin character and renal toxicity risk, whereas higher substitution raises hygroscopicity and osmolality without proportional solubilization gain for many APIs. Residual β-cyclodextrin is limited to ≤1.5% by chromatographic or electrophoretic methods. Water content is controlled by Karl Fischer titration USP ‹921›, with a typical release acceptance of ≤10.0% for amorphous powder. Parenteral batches are evaluated for bacterial endotoxins by USP ‹85›; the specific limit is derived from the maximum intended daily dose and route-specific K/M factors. Residual 1,4-butanesultone is controlled as a potential genotoxic impurity under ICH M7. Residual solvents are tested by headspace GC according to USP ‹467› and ICH Q3C; elemental impurities follow ICH Q3D using USP ‹233›. The product should not be released from quarantine until all monograph parameters and route-specific internal limits are satisfied.

Native β-cyclodextrin has aqueous solubility of only 18.5 g/L at 25 °C. Intravenous administration of native β-cyclodextrin is precluded by renal tubular precipitation and erythrocyte membrane phospholipid extraction, leading to nephrotoxicity and hemolysis. Sulfobutylation disrupts the intermolecular hydrogen-bond network that limits native α- and β-cyclodextrin solubility; the ionic sulfobutyl side chains remain hydrated and prevent crystal packing, converting SBECD into an amorphous, rapidly dissolving host. In vitro hemolysis studies show reduced membrane disruption compared with native β-cyclodextrin at equivalent molar concentration, which supports its use in parenteral formulations such as voriconazole and carfilzomib injections. The high aqueous solubility above 500 mg/mL at 25 °C enables liquid concentrates that cannot be prepared with unmodified β-cyclodextrin.

Degree of substitution directly controls the number of ionic groups and the macrocycle’s conformational flexibility. A substitution degree below 6.2 leaves segments of native β-CD that increase the residual β-cyclodextrin limit and may raise hemolytic potential; above 6.9 the product becomes more hygroscopic and increases osmolality without proportional gain in solubilization for many APIs. Capillary electrophoresis separates positional isomers of sulfobutyl substitution and is preferred when pharmacokinetic consistency requires tight batch-to-batch control. NMR spectroscopy gives the average degree of substitution but may not quantify positional isomer distribution with the same resolution. The selection of CE or NMR triggers different acceptance criteria across compendial monographs and should be fixed in the regulatory dossier rather than changed during commercial scale-up. Batch-to-batch variability of degree of substitution may affect complexation capacity, osmolality, and dissolution behavior; a narrow degree-of-substitution specification is therefore the main quality-control lever for injectable products.

Compaction, Moisture Uptake, and Solid-State Stability in SBECD-Containing Tablets and Granules

SBECD behaves as a glassy amorphous solid under dry conditions; the glass transition temperature is formulation-dependent and is significantly depressed by absorbed water. Moisture uptake can exceed 5% within 24 h at 75% RH, shifting the material from a free-flowing powder to a sticky agglomerate. Tablet manufacture should therefore use closed containment or a low-humidity suite, and immediate film coating after core compression is recommended. SBECD can reduce API crystallinity during wet granulation or spray drying; the resulting amorphous complex may require a maturation step to reach constant dissolution performance across batches. In capsule filling, hydrophobic lubricants can be reduced because SBECD granules are not as shear-sensitive as purely metallic stearate blends; however, the ionic sodium sulfonate groups can interact with acidic enteric polymers at the film-coating interface, causing tackiness if coating-pan exhaust humidity exceeds 60% RH.

In high-shear wet granulation, SBECD is first dissolved in purified water or a hydroalcoholic binder solution, then sprayed onto the drug-containing powder bed at a solution concentration of 10%–30% w/w. Granulation end point is monitored by impeller torque or power consumption rather than by time alone; overwetting produces adhesive granules that stick to the bowl and fluid-bed distributor plate. For tablet compression, SBECD-containing granules are often blended with microcrystalline cellulose, crospovidone, and magnesium stearate; compression force is adjusted to maintain friability ≤1% under USP ‹1216›. Direct compression with SBECD alone is not recommended because the amorphous powder exhibits poor flow and a flat particle surface; angle of repose often exceeds 40° when measured by USP ‹1174›. If the formulation contains moisture-sensitive actives, dry granulation is preferred, but published data for SBECD in roller compaction is limited.

SBECD can be incorporated into capsules by mixing the complexed drug with fillers such as lactose monohydrate or anhydrous dicalcium phosphate. Because SBECD is amorphous and hygroscopic, direct-filled capsules may show retarded shell dissolution if gelatin cross-linking occurs; shell brittleness is monitored by USP ‹711› dissolution and conditioned storage. In capsules, the use of SBECD does not eliminate the need for disintegrant; experimental batches often retain croscarmellose sodium or sodium starch glycolate at 2%–5% w/w to achieve disintegration times below 15 min in water at 37 °C. Granules for sachets or dry syrups are preferably produced by wet granulation because dissolved SBECD acts as binder and complexation medium simultaneously; granule hardness and re-dispersion time are optimized by adjusting water quantity and impeller speed.

Spray-dried dispersions containing SBECD require the excipient to remain in solution during atomization; the feed solution is typically prepared at 5%–20% w/w total solids and filtered through a clarifying filter before the high-pressure nozzle. Inlet air temperature is selected such that the outlet temperature remains below the softening point of the drug-SBECD complex; typical values for aqueous feeds are 120–140 °C inlet and 50–70 °C outlet. The dried dispersion is collected in a cyclone and sieved through a 250 µm screen to remove oversize agglomerates. Residual moisture after spray drying should be verified by Karl Fischer USP ‹921› because amorphous dispersions with free water above 3% may plasticize and recrystallize during storage.

Dissolution testing of SBECD-containing tablets should use USP apparatus II at 50 rpm or apparatus I at 100 rpm, with media selected to minimize complex disruption. If the dissolution medium contains high chloride or bile salts, apparent release may not reflect in vivo performance. Published data for this specific configuration is limited, but media shift testing at pH 1.2, 4.5, and 6.8 is standard because the ionization state of the drug and the complex changes across gastrointestinal regions. Sink conditions should be maintained without surfactant initially, since surfactant micelles may compete for the cyclodextrin cavity.

If the Sulfobutyl Ether Substituent Is Ionized Below pH 1, How Does That Change Complexation Relative to Hydroxypropyl Betadex?

The sulfonate group pKa is below 1.0; therefore, SBECD carries multiple negative charges under gastric, intestinal, and blood pH conditions. Hydroxypropyl betadex (HPBCD) is non-ionic and may be preferred for neutral lipophilic drugs because it avoids ionic strength-dependent binding. SBECD adds a coulombic term to inclusion binding: protonated amine drugs can associate with both the cyclodextrin cavity and the sulfonate shell, increasing apparent complexation efficiency for basic compounds. Conversely, anionic drugs may show reduced binding due to electrostatic repulsion, and high chloride concentrations in physiological saline can compete for cationic drug-sulfonate interactions, reducing apparent stability constants. This makes SBECD less predictable than HPBCD in simulated gastric fluid; phase-solubility curves may be nonlinear because of simultaneous 1:1 and higher-order complexes. Formulators should compare stability constants in USP biorelevant media at ionic strengths of 0.01 M, 0.05 M, and 0.15 M NaCl before committing to SBECD over HPBCD.

For injectables, SBECD is reconstituted into Water for Injection under nitrogen or vacuum mixing until a clear concentrate is obtained. The drug is typically added at a molar SBECD:drug ratio of 10:1 to 100:1; higher ratios may be required for weakly basic APIs with high crystallinity or pronounced self-association. The solution is pH-adjusted and sterile-filtered through a 0.22 µm PVDF or PES membrane before aseptic filling or lyophilization. Because SBECD is a synthetic polysulfonate polyelectrolyte, it contributes to tonicity and can raise osmolality above the preferred peripheral infusion range; osmolality is measured by USP ‹785› and adjusted with sodium chloride or dextrose. Benzalkonium chloride and other positively charged preservatives may partition into the SBECD cavity or associate with sulfonate groups; multi-dose injectables should be screened with antimicrobial effectiveness testing USP ‹51› to confirm preservative efficacy. SBECD is not a tonicity agent, buffering agent, or primary stabilizer; it is a functional carrier whose concentration must be justified by phase-solubility and stability data.

Terminal moist-heat sterilization of SBECD solutions can catalyze hydrolysis of the cyclodextrin macrocycle at the glycosidic bonds, particularly at pH values below 4.0 or above 8.0. Autoclaving should be evaluated by plotting pH, peak area of degradation products, and sub-visible particles after cycles at 121 °C for 15 min. If the API is thermolabile, aseptic filtration is preferred. Sterilizing-grade filters must be qualified because SBECD solutions can exhibit high viscosity at concentrations above 30% w/w, reducing flux through small-area capsules. Filter compatibility studies using 0.22 µm PVDF and PES membranes and pressure-decay leakage tests are part of process validation. For lyophilized products, SBECD remains amorphous and contributes bulk; the collapse temperature is product-specific and must be determined before primary drying.

Storage and regulatory status must reflect the intended route. SBECD is cited in the FDA Inactive Ingredient Database for approved injectable and oral drug products, but the applicant must verify the specific route, maximum daily exposure, and regional monograph status for the finished product. Bulk containers should be kept tightly closed, protected from light, and stored at controlled room temperature unless otherwise stated; once opened, an inert-gas overlay and desiccant monitoring are recommended because the material adsorbs atmospheric moisture. Analytical release should include identity by infrared or NMR, degree of substitution, chloride and sulfobutyl ether content, residual β-cyclodextrin, water content, microbial enumeration, and endotoxin when the batch is allocated to parenteral manufacturing. The choice between SBECD and other cyclodextrins should be made by comparative phase-solubility screening, not by solubility of the excipient alone; operational boundaries include the drug’s pKa, long-term stability of the complex, and the final route-specific osmolality limit.